Evolving guidelines in the use of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis

BMC Musculoskeletal Disorders

Casilda M Balmaceda¹ 

[1] NY Neurological Consultants, PC, 300 Fort Washington Avenue, Suite 1, New York 10032, New York

关键词: Guidelines;    Topical;    NSAIDs;    Pain;    Osteoarthritis;   

Others  :  1128872
DOI  :  10.1186/1471-2474-15-27

 received in 2013-03-18, accepted in 2013-10-31,  发布年份 2014

【 摘 要 】

Background

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a standard treatment for osteoarthritis (OA), but the use of oral NSAIDs has been linked to an elevated risk for cardiovascular and gastrointestinal adverse events and renal toxicity. Topical NSAIDs are thought to afford efficacy that is comparable to oral formulations while reducing widespread systemic drug exposure, which may provide a benefit in terms of safety and tolerability. As a result, European treatment guidelines have, for many years, recommended the use of topical NSAIDs as a safe and effective treatment option for OA. Following the recent approval of several topical NSAID formulations by the US Food and Drug Administration, US treatment guidelines are increasingly recommending the use of topical NSAIDs as an alternative therapy and, in some cases, as a first-line option for OA. This commentary summarizes OA treatment guidelines that are currently available and discusses their potential evolution with regard to the increased inclusion of topical NSAIDs.

【 授权许可】

   
2014 Balmaceda; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF: Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000, 133:635-646.
• [2]Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK: Prevalence and burden of osteoarthritis: results from a population survey in Norway. J Rheutmatol 2008, 35:677-684.
• [3]Salaffi F, Carotti M, Stancati A, Grassi W: Health-related quality of life in older patients with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res 2005, 17:255-263.
• [4]Kadam UT, Jordan K, Croft PR: Clinical comorbidity in patients with osteoarthritis: a case–control study of general practice consulters in England and Wales. Ann Rheum Dis 2004, 63:408-414.
• [5]Chan KW, Ngai HY, Ip KK, Lam KH, Lai WW: Co-morbidities of patients with knee osteoarthritis. Hong Kong Med J 2009, 15:168-172.
• [6]Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F, on behalf of the National Arthritis Data Workgroup: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35.
• [7]Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA: Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum 2009, 60:3546-3553.
• [8]Attur M, Samuels J, Krasnokutsky S, Abramson SB: Targeting the synovial tissue for treating osteoarthritis (OA): where is the evidence? Best Pract Res Clin Rheumatol 2010, 24:71-79.
• [9]Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P: American college of rheumatology 2012 recommendations for the use of Nonpharmacologic and pharmacologic therapies for osteoarthritis of the hand, hip and knee. Arthritis Care Res (Hoboken) 2012, 64:465-474.
• [10]Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M, on behalf of the Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT: EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
• [11]National Collaborating Centre for Chronic Conditions: Osteoarthritis: National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians; 2008.
• [12]Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
• [13]Roth SH: Nonsteroidal antiinflammatory drug gastropathy: we started it, why don’t we stop it? J Rheumatol 2005, 32:1189-1191.
• [14]Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY: Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004, 63:759-766.
• [15]Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, on behalf of the American Heart Association: Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007, 115:1634-1642.
• [16]Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J: Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 2006, 29:621-632.
• [17]Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA: Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005, 45:531-539.
• [18]Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106:13S-24S.
• [19]Boers M, Tangelder MJ, Van Ingen H, Fort JG, Goldstein JL: The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis 2007, 66:417-418.
• [20]Hippisley-Cox J, Coupland C, Logan R: Risk of adverse gastrointestinal outcomes in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case–control analysis. BMJ 2005, 331:1310-1316.
• [21]Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Knostam MA, Baron JA, on behalf of the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med 2005, 352:1092-1102.
• [22]Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, on behalf of the Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005, 352:1071-1080.
• [23]Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, on behalf of the VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000, 343:1520-1528.
• [24]Barkin RL, Beckerman M, Blum SL, Clark FM, Koh EK, Wu DS: Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010, 27:775-789.
• [25]Altman RD, Barthel HR: Topical therapies for osteoarthritis. Drugs 2011, 71:1259-1279.
• [26]Roth SH, Fuller P: Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis. J Pain Res 2011, 4:159-167.
• [27]Taylor RS, Fotopoulos G, Maibach H: Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions. Curr Med Res Opin 2011, 27:605-622.
• [28]Rainsford KD, Kean WF, Ehrlich GE: Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. Curr Med Res Opin 2008, 24:2967-2992.
• [29]Kienzler JL, Gold M, Nollevaux F: Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol 2010, 50:50-61.
• [30]Tanojo H, Wester RC, Shainhouse JZ, Maibach HI: Diclofenac metabolic profile following in vitro percutaneous absorption through viable human skin. Eur J Drug Metab Pharmacokinet 1999, 24:345-351.
• [31]Klinge SA, Swayer GA: Effectiveness and safety of topical versus oral nonsteroidal anti-inflammatory drugs: a comprehensive review. Phys Sports Med 2013, 41:64-74.
• [32]Derry S, Moore RS, Rabbie R: Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2012., (Issue 9) Art. No.: CD007400. doi:10.1002/14651858.CD007400.pub2
• [33]Rosemont IL: Treatment of Osteoarthritis of the Knee Evidence-Based Guideline 2nd Edition. American Academy of Orthopaedic Surgeons; 2013.
• [34]Simon LS, Lipman AG, Jacox AK, Caudill-Slosberg M, Gill LH, Keefe FJ, Kerr KL, Minor MA, Sherry DD, Vallerand AH, Vasudevan S: Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis. 2nd edition. American Pain Society: Glenview, IL; 2002. [Clinical Practice Guidelines no. 2]
• [35]American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons: Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009, 57:1331-1346.
• [36]Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, Dinçer F, Dziedzic K, Häuselmann HJ, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Maheu E, Martín-Mola E, Pavelka K, Punzi L, Reiter S, Sautner J, Smolen J, Verbruggen G, Zimmermann-Górska I: EULAR evidence based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2007, 66:377-388.
• [37]Lim AY, Doherty M: What of guidelines for osteoarthritis? Int J Rheum Dis 2011, 14:136-144.
• [38]Towheed TE: Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2006, 33:567-573.
• [39]Trnavský K, Fischer M, Vögtle-Junkert U, Schreyger F: Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis. Results of a randomized, double-blind, placebo-controlled study. J Rheumatol 2004, 31:565-572.
• [40]Niethard FU, Gold MS, Solomon GS, Liu JM, Unkauf M, Albrecht HH, Elkik F: Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol 2005, 32:2384-2392.
• [41]Altman RD, Dreiser RL, Fisher CL, Chase WF, Dreher DS, Zacher J: Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009, 36:1991-1999.
• [42]Simon LS, Grierson LM, Naseer Z, Bookman AA, Shainhouse JZ: Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009, 143:238-245.
• [43]Peniston JH, Gold MS, Wieman MS, Alwine LK: Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. Clin Intervent Aging 2012, 7:517-523.